AzTrials
AzTrials

Metabolic Associated Fatty Liver DiseaseNCT04871880

Lifestyle Modification for MAFLD Based on TTM

A study testing Dietitian led life style modification intervention in people with Metabolic Associated Fatty Liver Disease, run by Nanfang Hospital, Southern Medical University at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Lifestyle changes aiming at weight loss remain the cornerstone of MAFLD treatment.Evaluating the motivational stage of patients' change and providing targeted lifestyle guidance may significantly improve the efficiency of weight loss. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Metabolic Associated Fatty Liver Disease
What is being tested?
Dietitian led life style modification intervention
Could I receive a placebo?
No, everyone receives an active treatment
How many people
75 participants
Where
1 siteChina
Study dates
17 May 2020to 30 Dec 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • With age range of 18-65 years.
  • BMI ≥ 28kg/m2
  • Fatty infiltration of the liver was confirmed on imaging studies (ultrasound, transient elastography, computed tomography, or magnetic resonance imaging) or liver biopsy.
  • With valid motivational stage assessment based on TTM.
  • Written consent form obtained.

Who cannot join

  • History of other chronic liver disease (Viral hepatitis B or C, autoimmune hepatitis, cholestatic and Inherited metabolic liver diseases) and hemochromatosis.
  • Self-reported HIV-positive status, active tuberculosis, active malaria, or inflammatory bowel disease.
  • Excessive alcohol consumption (>30g/d for men and >20g/d for women).
  • Patient has known cirrhosis (compensated/decompensated) either based on clinical criteria or liver histology or Imaging techniques.
  • Subjects using thyroid hormones, oestrogens, amiodarone, steroids, tamoxifen and other medicine known to affect liver fat accumulation.
  • Subjects using thiazolidinedione hypoglycemic drugs, vitamin E and other medicine have potential benefits for NASH within six months.
Show all 18Show fewer
  • Subjects with organ failure.
  • Subjects with hepatocellular carcinoma or other active malignancy.
  • Solid organ transplant recipients.
  • Antibiotic treatment within the previous 3 months.
  • Suffering from any acute or chronic cardiovascular, GI or immunological condition.
  • Gastric or duodenal ulcer in the past six months.
  • Currently pregnant or nursing.
  • Concomitant diseases with reduced life expectancy.
  • Combined mental illness.
  • Contraindication to MRI scanning.
  • Exclusions may also be made at the discretion of the attending physician or the eligibility committee.
  • Inability to provide informed consent.

Trial locations and contacts

1 site in 1 country.

China1 site, 1 recruiting
  • Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong

    Jinjun Chen, 86-18588531001, chjj@smu.edu.cn

    Ling Zhou, 86-13631383539, vzhouling3168@163.com

    Recruiting

Other trials in China

About this study

Official title: Lifestyle Modification for the Treatment of Metabolic Associated Fatty Liver Disease Based on Transtheoretical Model: a Single-center, Randomized, Controlled Study

Lifestyle changes aiming at weight loss remain the cornerstone of MAFLD treatment.Evaluating the motivational stage of patients' change and providing targeted lifestyle guidance may significantly improve the efficiency of weight loss. The investigators hypothesize that gut microbiota may affect motivation to lose weight, and the changes in gut microbiota due to weight loss may positively feedback the behavior of motivation, forming a virtuous circle. Thus, this study aims at ①evaluating the relationships between motivational stage of weight loss and the gut microbiota (Gut-brain axis); ②investigating the effects of lifestyle interventions on the gut microbiota in MAFLD patients.

Read the detailed description

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population, and has no approved drug therapy. In 2020, two position articles have proposed not only the change of the terminology from NAFLD to metabolic associated fatty liver disease (MAFLD), but also an update and revision of the definition of fatty liver disease. According to these papers, indeed, the diagnosis of MAFLD can be made with the presence of hepatic steatosis (detected by serum biomarker scores, imaging methods or histology) and at least one of the fol- lowing metabolic criteria: (a) overweight/obesity, (b) T2DM and (c) metabolic dysregulation (that means at least two factors among increased waist circumference, hypertension, hypertriglyceridemia, low serum HDL-cholesterol levels, impaired fasting glucose, homeostatic model assessment of insulin resistance [HOMA-IR] > 2.5 or high sensitivity C-reactive protein > 2 mg/L). Here,the investigators focus on the obese NAFLD, which considered as a sub-phenotype in MAFLD.

Lifestyle changes aiming at weight loss remain the cornerstone of MAFLD treatment. However, it is not easy to make patients change their unhealthy lifestyle. Behavior therapy may only be successful in motivated patients, and motivation to dieting and exercising may be different according to age and sex. Personal motivation for change plays a pivotal role in behavior changes. The transtheoretical model (TTM) is an empirically validated model of individual behavioral change, which involves progress through a series of stages to make a particular behavioral change. TTM-based interventions have been applied to facilitate health behavioral changes, such as physical exercise, smoking cessation, and weight management, studies of which continue to demonstrate positive effects. Evaluating the motivational stage of patients' change and providing targeted lifestyle guidance may significantly improve the efficiency of weight loss. The investigators hypothesize that gut microbiota may affect motivation to lose weight, and the changes in gut microbiota due to weight loss may positively feedback the behavior of motivation, forming a virtuous circle.

Thus, a total of seventy obese patients with NAFLD will be recruited in this study, divided into lifestyle modification program group(n=35) and usual care group(n=35). All subjects will undergo dietary assessment based on Food Frequency Questionnaire ( FFQ) and motivational stages evaluation based on TTM. Stool samples will be collected at each visit. Demographic data will be recorded, consisted of age, weight, height, waist circumference, BMI, and so on. MRI-PDFF will be performed to evaluate liver steatosis. Meanwhile, vibration-controlled transient elastography will be carried out, which include liver stiffness (LSM) and controlled attenuation parameter (CAP) measurements. Biochemistry tests will be conducted as supplementary for assessment of NAFLD and cardiovascular risks, comprising liver function test, lipid, fasting glucose, etc.

The investigators aim at ①evaluating the relationships between motivational stage of weight loss and the gut microbiota (Gut-brain axis); ②investigating the effects of lifestyle interventions on the gut microbiota in MAFLD patients.

Being tested
Dietitian led life style modification intervention, Conventional care (control)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Dietitian led life style modification interventionBehavioural

    All participants received recommendations for a low-fat hypocaloric diet that was 750 kcal/day less than their daily energy need which supervised by dietitians. Additionally, patients were encouraged to walk 200 minutes per weeks and a short self-report questionnaire for the measurement of habitual physical activity was implemented at baseline, 4, 16, 32 and 48 weeks.

  • Conventional care (control)Behavioural

    Receive routine care

Study groups in NCT04871880
Study groupRoleWhat they receive
Dietitian led life style modification intervention.ExperimentalLifestyle changes supervised by dietitians
Receives: Behavioral: Dietitian led life style modification intervention
Conventional care (control)ExperimentalReceive routine care
Receives: Behavioral: Conventional care (control)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Hepatic fat

    Change of liver proton density fat fraction (PDFF) in MAFLD assessed by magnetic resonance imaging (MRI)

    Measured: 12 months

  2. Obesity

    Changes in body weight

    Measured: 1, 4, 8, 12, 24 months

  3. Gut microbiota

    Changes in bacterial component of the gut microbiome

    Measured: 1, 4, 8, 12, 24 months

Secondary outcomes (9)
  1. Blood pressure

    Changes in blood pressure

    Measured: 1, 4, 8, 12, 24 months

  2. Central obesity

    Changes in waist circumference

    Measured: 1, 4, 8, 12, 24 months

  3. Insulin resistance

    Changes in insulin resistance eveluated by HOMA-IR

    Measured: 1, 4, 8, 12, 24 months

  4. FPG

    Changes in fast plasma glucose

    Measured: 1, 4, 8, 12, 24 months

  5. HbA1c

    Changes in HbA1c

    Measured: 1, 4, 8, 12, 24 months

  6. Plasma triglycerides

    Changes in plasma triglycerides

    Measured: 1, 4, 8, 12, 24 months

  7. Plasma HDL-cholesterol

    Changes in plasma HDL-cholesterol

    Measured: 1, 4, 8, 12, 24 months

  8. Plasma high-sensitivity C-reactive protein level

    Changes in plasma high-sensitivity C-reactive protein level

    Measured: 1, 4, 8, 12, 24 months

  9. Gut microbiota diversity

    Changes in diversity of gut microbiome(α-diversity and β-diversity)

    Measured: 1, 4, 8, 12, 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 May 2021
  2. Study start17 May 2020
  3. Primary completion17 May 2024 (estimated)
  4. Study completion30 Dec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
75 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04871880
Sponsor's protocol ID
NFEC-2019-254
Status last verified
Apr 2021
First submitted
20 Apr 2021
Last updated
4 May 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Dietitian led life style modification intervention in people with Metabolic Associated Fatty Liver Disease, run by Nanfang Hospital, Southern Medical University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 May 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Jinjun Chen (8618588531001, chjj@smu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Hepatic fat (time frame: 12 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in